Ministry of Health confirms child’s medical coverage
health, cp24 stock, medical, doctor
Published Thursday, August 9, 2012 9:03AM CST
Last Updated Thursday, August 9, 2012 1:42PM CST
The Saskatchewan Ministry of Health confirms it has approved coverage of a new drug for a three-year old girl from Langenburg Saskatchewan.
Violet Revet suffers from a rare enzyme deficiency condition, mucopolysaccharidosis VI, (MPS VI), also known as Maroteaux-Lamy Syndrome. Individuals with MPS VI suffer from skeletal deformities, joint disease, and cardiopulmonary disease.
The ministry says the request to cover the drug, Naglazyme, was received by the Saskatchewan Drug Plan on July 9, 2012. The ministry says officials weighed the drug's clinical effectiveness, cost and safety in coming to their decision.
The approved weekly treatment is an enzyme replacement therapy. The annual cost is upward of $300,000.
There are nine confirmed cases of MPS VI in Canada.